Biomerieux

Biomerieux EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biomerieux (BIM.PA) as of Nov 21, 2026 is 728.00 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 623.90 M EUR — a change of 16.69% (higher).

EBITDA

728.00 MEUR

YoY

16.69%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biomerieux is 2025 728.00 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biomerieux was 2024 623.90 M EUR. It decreases by 16.69% higher compared to the previous year.

The Biomerieux EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
381.00 M EUR
Jan 1, 2019
348.80 M EUR
Jan 1, 2020
568.70 M EUR
Jan 1, 2021
827.70 M EUR
Jan 1, 2022
636.40 M EUR
Jan 1, 2023
487.60 M EUR
Jan 1, 2024
623.90 M EUR
Jan 1, 2025
728.00 M EUR
The Biomerieux EBITDA history
YEAREBITDAYoY
728.00 MEUR+16.69%
623.90 MEUR+27.95%
487.60 MEUR-23.38%
636.40 MEUR-23.11%
827.70 MEUR+45.54%
568.70 MEUR+63.04%
348.80 MEUR-8.45%
381.00 MEUR+7.96%
352.90 MEUR+11.50%
316.50 MEUR+13.60%
278.60 MEUR+14.70%
242.90 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerieux Stock analysis

What does Biomerieux do? Biomerieux SA is a French company that operates in the field of in vitro diagnostics. The company was founded in 1963 by French biologist Alain Merieux and has since continued to grow. Today, Biomerieux employs around 12,000 people in over 150 countries worldwide and is listed on the Paris Stock Exchange. Biomerieux's business model is based on the development, production, and marketing of diagnostic products for various areas of medicine. This includes infectious diseases, cancer, and cardiovascular diseases. The company is divided into two main business segments: Clinical Diagnostics and Industrial Microbiology. Under the Clinical Diagnostics segment, Biomerieux offers a wide range of diagnostic products for infectious diseases, including molecular diagnostics, blood-based tests, and laboratory automation solutions. Some of the most well-known products include the VIDAS immunodiagnostic test, the FilmArray multiplex PCR test, and the VITEK automated system for microorganism identification. Under the Industrial Microbiology segment, Biomerieux is a leading provider of products for the microbiological analysis of food, beverages, and pharmaceutical products. The company offers a wide range of products for microbiological quality control, which help ensure the safety and quality of food and pharmaceutical products. These include the TEMPO system for assessing microorganism growth and the Bactalert blood culture system for rapid detection of bacteria in blood cultures. In addition to its main business segments, Biomerieux also offers specialty products for use in veterinary diagnostics and water analysis. The company works closely with clinical laboratories and health authorities to improve the diagnosis of infectious diseases and combat epidemics. Over the years, Biomerieux has built a strong research and development department focused on developing innovative diagnostic products. The company has also made a number of strategic acquisitions to expand its product portfolio and enter new markets. For example, in 2020, Biomerieux acquired Suzhou Hybiome Biomedical Engineering in China to strengthen its presence in the Chinese market. In summary, Biomerieux is a leading company in the field of in vitro diagnostics. Its wide range of products and global network make it an important partner for laboratories, hospitals, and the food and pharmaceutical industries. With its strong research and development department and strategic acquisitions, Biomerieux will continue to play a crucial role in the fight against infectious diseases and the improvement of patient care. Biomerieux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerieux stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biomerieux is 728.00 M EUR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biomerieux changed from 623.90 M EUR to 728.00 M EUR, representing a 16.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Biomerieux since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Biomerieux historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biomerieux

All Key Metrics — Biomerieux